Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
De-risking Biologics Development Through Advanced Mass Spectrometry Approaches
Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.